<DOC>
	<DOCNO>NCT01868477</DOCNO>
	<brief_summary>The primary purpose trial ass effect treatment deferasirox combine erythropoietin vs. erythropoietin alone erythropoiesis patient low- int-1-risk myelodysplastic syndrome . The addition deferasirox erythropoietin could lead potential synergism reduction reactive oxygen specie , NF-kB pathway control free toxic iron . This may create good environment bone marrow well response erythropoietin . This study design test prospective way combination deferasirox erythropoietin term effect hematopoiesis .</brief_summary>
	<brief_title>Combination Study Deferasirox Erythropoietin Patients With Low- Int-1-risk Myelodysplastic Syndrome .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients low Int1risk myelodysplastic syndrome Documented diagnosis follow : Myelodysplastic syndrome last ≥ 3 month &lt; 3 year Disease must secondary treatment radiotherapy , chemotherapy , and/or immunotherapy malignant autoimmune diseases A hemoglobin &lt; 10 g/dL ≥ 8 g/dL History transfusion &lt; 10 RBC unit must RBC transfusion dependent 300 ng/mL &lt; serum ferritin &lt; 1,500 ng/mL ( Values within 10 % difference 1500 ng/ml 10 % difference 300 ng/ml may accept investigator 's discretion . Endogenous erythropoietin level &lt; 500 units/L Patients MDS isolate del ( 5q ) Patients receive prior EPO treatment recombinant growth factor regardless outcome ( Patient receive prior EPO treatment recombinant growth factor le 4 week within 3 month screen without document response allow ) Patients receive steroid immunosuppressive therapy improvement hematological parameter ( stable steroid treatment adrenal failure chronic medical condition , intermittent dexamethasone antiemetic allow ) . B12 folate deficient patient without clinical symptom ( patient could rescreened successful therapy B12 folate deficiency ) Uncontrolled seizure uncontrolled hypertension Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>myelodysplasia</keyword>
	<keyword>blood disorder</keyword>
	<keyword>cytopenia</keyword>
	<keyword>low blood count</keyword>
	<keyword>progressive bone marrow failure</keyword>
</DOC>